NASDAQ: APYX | Healthcare / Medical Devices & Instruments / USA |
2.92 | +0.0500 | +1.74% | Vol 54.09K | 1Y Perf -54.66% |
Mar 24th, 2023 16:00 DELAYED |
BID | 2.70 | ASK | 3.09 | ||
Open | 2.80 | Previous Close | 2.87 | ||
Pre-Market | - | After-Market | 2.83 | ||
- - | -0.09 -3.08% |
Target Price | 4.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 36.99 | Finscreener Ranking | ★★★★ 53.17 | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 51.33 | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 50.07 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
Price Range Ratio 52W % | 16.35 | Earnings Rating | Strong Sell | |
Market Cap | 101.02M | Earnings Date | 11th May 2023 | |
Alpha | 0.03 | Standard Deviation | 0.21 | |
Beta | 1.11 |
Today's Price Range 2.752.92 | 52W Range 1.3111.16 | 5 Year PE Ratio Range -18.605.00 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 0.34% | ||
1 Month | 1.74% | ||
3 Months | 46.73% | ||
6 Months | -39.17% | ||
1 Year | -54.66% | ||
3 Years | -20.44% | ||
5 Years | -2.34% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -16.46 | |||
ROE last 12 Months | -43.48 | |||
ROA (5Y Avg) | -13.95 | |||
ROA last 12 Months | -33.97 | |||
ROC (5Y Avg) | 9.47 | |||
ROC last 12 Months | -39.34 | |||
Return on invested Capital Q | -12.98 | |||
Return on invested Capital Y | -3.69 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 1.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-4.60 | ||||
2.13 | ||||
2.66 | ||||
133.80 | ||||
-5.40 | ||||
-0.45 | ||||
2.13 | ||||
1.21 | ||||
75.24M | ||||
Forward PE | -5.29 | |||
PEG | -0.31 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.80 | ||||
4.10 | ||||
0.01 | ||||
0.02 | ||||
-1 450.80 | ||||
Leverage Ratio | 1.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
67.80 | ||||
-38.70 | ||||
-36.80 | ||||
-48.90 | ||||
-53.96 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
31.90M | ||||
0.92 | ||||
20.62 | ||||
2.71 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2022 | - | -0.17 | - |
Q03 2022 | -0.12 | -0.17 | -41.67 |
Q02 2022 | -0.20 | -0.16 | 20.00 |
Q01 2022 | -0.13 | -0.17 | -30.77 |
Q04 2021 | -0.13 | -0.06 | 53.85 |
Q03 2021 | -0.15 | -0.12 | 20.00 |
Q02 2021 | -0.14 | -0.12 | 14.29 |
Q01 2021 | -0.14 | -0.14 | 0.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 QR | -0.14 | -100.00 | Negative |
12/2022 FY | -0.64 | -23.08 | Negative |
3/2023 QR | -0.12 | 7.69 | Positive |
12/2023 FY | -0.55 | -27.91 | Negative |
Next Report Date | 11th May 2023 |
Estimated EPS Next Report | -0.06 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 54.09K |
Shares Outstanding | 34.60K |
Shares Float | 33.31M |
Trades Count | 279 |
Dollar Volume | 156.10K |
Avg. Volume | 157.93K |
Avg. Weekly Volume | 62.55K |
Avg. Monthly Volume | 186.62K |
Avg. Quarterly Volume | 224.62K |
Apyx Medical Corporation (NASDAQ: APYX) stock closed at 2.92 per share at the end of the most recent trading day (a 1.74% change compared to the prior day closing price) with a volume of 54.09K shares and market capitalization of 101.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 266 people. Apyx Medical Corporation CEO is Charles D. Goodwin.
The one-year performance of Apyx Medical Corporation stock is -54.66%, while year-to-date (YTD) performance is 24.79%. APYX stock has a five-year performance of -2.34%. Its 52-week range is between 1.31 and 11.155, which gives APYX stock a 52-week price range ratio of 16.35%
Apyx Medical Corporation currently has a PE ratio of -4.60, a price-to-book (PB) ratio of 2.13, a price-to-sale (PS) ratio of 2.66, a price to cashflow ratio of 133.80, a PEG ratio of 2.32, a ROA of -33.97%, a ROC of -39.34% and a ROE of -43.48%. The company’s profit margin is -53.96%, its EBITDA margin is -36.80%, and its revenue ttm is $31.90 Million , which makes it $0.92 revenue per share.
Of the last four earnings reports from Apyx Medical Corporation, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Apyx Medical Corporation’s next earnings report date is 11th May 2023.
The consensus rating of Wall Street analysts for Apyx Medical Corporation is Strong Buy (1), with a target price of $4, which is +36.99% compared to the current price. The earnings rating for Apyx Medical Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Apyx Medical Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Apyx Medical Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.17, ATR14 : 0.24, CCI20 : -20.76, Chaikin Money Flow : 0.20, MACD : -0.07, Money Flow Index : 34.43, ROC : -0.68, RSI : 50.66, STOCH (14,3) : 61.11, STOCH RSI : 1.00, UO : 51.86, Williams %R : -38.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Apyx Medical Corporation in the last 12-months were: Andrew Makrides (Option Excercise at a value of $76 200), Charles D. Goodwin (Buy at a value of $70 068), Lawrence J. Waldman (Option Excercise at a value of $83 280), Michael Geraghty (Option Excercise at a value of $26 900), Moshe Citronowicz (Option Excercise at a value of $76 200)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.
CEO: Charles D. Goodwin
Telephone: +1 727 384-2323
Address: 5115 Ulmerton Road, Clearwater 33760, FL, US
Number of employees: 266
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.